Last reviewed · How we verify
Metformin IR tablets
At a glance
| Generic name | Metformin IR tablets |
|---|---|
| Also known as | Treatment A (Reference) |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets (PHASE1)
- Tolerability Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets (PHASE1)
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) (PHASE3)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes (PHASE4)
- Metformin Therapy in Non-diabetic AAA Patients (PHASE2, PHASE3)
- Investigational Study of Delayed Release Metformin (PHASE3)
- SGLT2 Inhibitors in Patients With PCOS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |